• Gilead posted a press release on Phase 3 ISLEND-1 and ISLEND-2 results for once-weekly oral islatravir/lenacapavir in virologically suppressed adults.
• Week 48 primary endpoints showed noninferior viral suppression versus Biktarvy in ISLEND-1, daily standard-of-care regimens in ISLEND-2.
• Data slated for late-breaking presentation at AIDS 2026 on July 29; results positioned to support regulatory filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607211000BIZWIRE_USPR_____20260720_BW061462) on July 21, 2026, and is solely responsible for the information contained therein.